2Q26 revenues of $901.6 million 2Q26 net income of $89.1 million, adjusted EBITDA (1) of $155.5 million 2Q26 diluted GAAP EPS of $0.97, non-GAAP (1) EPS of $1.07 Announced the sale of the medical business, enabling increased focus on core nuclear national defense and commercial nuclear power
August 3, 2026